Generic Name: gilteritinib
Drug Class: Targeted Therapy Medications
Approval Status: Approved
Generic Version Available: No
Xospata is a kinase inhibitor approved for treatment of adults with relapsed or refractory acute myeloid leukemia with an FLT3 mutation.
Xospata inhibits multiple receptor tyrosine kinases, including FMS-like tyrosine kinase 3
(FLT3), which plays a role in cell growth and production of new blood cells.
The Phase III ADMIRAL trial, which enrolled people with acute myeloid leukemia (AML) that recurred or did not respond to other therapies, showed that 21 percent of patients treated with Xospata achieved complete remission and a third no longer needed red blood cell transfusions. Xospata was approved for AML on November 28, 2018.
Xospata is taken as a tablet once daily.
Common side effects include muscle and joint pain, elevated liver enzymes, fatigue, fever, diarrhea, nausea, headache, dizziness, swelling and skin rash. Uncommon but potentially serious side effects may include encephalopathy, abnormal heart rhythm and pancreatitis. Xospata may cause fetal harm if used during pregnancy.
Last Reviewed: November 28, 2018